Description

MOQUET SR 300 MG

Indications

MOQUET SR 300 MG is primarily indicated for the management of chronic obstructive pulmonary disease (COPD) and asthma. It is used to relieve symptoms such as wheezing, shortness of breath, and chest tightness associated with these respiratory conditions. The formulation is designed for sustained release, providing prolonged therapeutic effects and improving patient compliance by reducing the frequency of dosing.

Mechanism of Action

MOQUET SR contains the active ingredient montelukast, which is a leukotriene receptor antagonist. Leukotrienes are inflammatory mediators that play a significant role in the pathophysiology of asthma and allergic rhinitis. By blocking the action of leukotrienes at their receptors, montelukast reduces bronchoconstriction, mucus secretion, and airway edema. This mechanism helps to improve lung function and decrease the frequency of asthma attacks and COPD exacerbations.

Pharmacological Properties

Montelukast exhibits a high affinity for the cysteinyl leukotriene receptor type 1 (CysLT1). It is well absorbed after oral administration, with peak plasma concentrations occurring within 3 hours. The bioavailability of montelukast is approximately 64%, and it is extensively metabolized in the liver via cytochrome P450 enzymes. The elimination half-life of montelukast is about 2.7 to 5.5 hours, allowing for once-daily dosing. The drug is primarily excreted in the feces, with less than 1% of the dose being excreted unchanged in the urine.

Contraindications

MOQUET SR 300 MG is contraindicated in patients with a known hypersensitivity to montelukast or any of its components. It should not be used as a rescue medication for acute asthma attacks or in patients with severe asthma exacerbations requiring immediate medical attention. Caution is advised when prescribing to patients with a history of psychiatric disorders, as montelukast has been associated with mood changes and behavioral issues in some individuals.

Side Effects

The use of MOQUET SR 300 MG may be associated with various side effects, although not all patients will experience them. Common side effects include headache, dizziness, fatigue, and gastrointestinal disturbances such as nausea and diarrhea. Rare but serious side effects may include allergic reactions, mood changes, and suicidal thoughts or behavior. Patients should be monitored for any unusual changes in behavior or mood, and if such symptoms occur, they should discontinue use and consult a healthcare provider.

Dosage and Administration

The recommended dosage of MOQUET SR 300 MG for adults and adolescents aged 15 years and older is one tablet taken orally once daily, preferably in the evening. For children aged 6 to 14 years, the dosage may be adjusted based on the physician’s assessment. It is important to take MOQUET SR at the same time each day to maintain consistent therapeutic levels in the bloodstream. Patients should not exceed the prescribed dose, and if a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose.

Interactions

Montelukast may interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Notable interactions include those with other medications metabolized by the cytochrome P450 system, such as phenobarbital, rifampicin, and certain antidepressants. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions. It is also advisable to avoid the concomitant use of MOQUET SR with other leukotriene receptor antagonists.

Precautions

Before starting treatment with MOQUET SR 300 MG, patients should discuss their medical history with their healthcare provider, particularly any history of liver disease, renal impairment, or psychiatric disorders. Special caution should be exercised in patients with asthma who are not adequately controlled, as montelukast is not intended as a substitute for inhaled corticosteroids or other long-term asthma control medications. Patients should be educated on the proper use of their asthma medication regimen and the importance of not using MOQUET SR as a rescue inhaler.

Clinical Studies

Clinical studies have demonstrated the efficacy of montelukast in improving lung function and reducing the frequency of asthma attacks. In a randomized controlled trial involving patients with moderate to severe asthma, those treated with montelukast showed significant improvements in forced expiratory volume (FEV1) and a reduction in the need for rescue medication compared to placebo. Additionally, studies have indicated that montelukast can improve quality of life in patients with asthma and reduce the incidence of exacerbations in those with COPD. Long-term studies have also suggested that montelukast is well-tolerated and maintains its efficacy over extended periods of treatment.

Conclusion

MOQUET SR 300 MG is an effective medication for the management of asthma and COPD, providing symptom relief and improving patients’ quality of life. Its mechanism of action as a leukotriene receptor antagonist offers a unique approach to controlling airway inflammation and bronchoconstriction. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions, and to use the medication responsibly as part of a comprehensive asthma or COPD management plan. Regular follow-up with healthcare providers is recommended to ensure optimal treatment outcomes.